Cambrex Corporation  

(Public, NYSE:CBM)   Watch this stock  
Find more results for CBM
21.79
+0.17 (0.79%)
Dec 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 21.63 - 21.94
52 week 15.20 - 24.45
Open 21.70
Vol / Avg. 99,886.00/193,820.00
Mkt cap 675.39M
P/E 17.35
Div/yield     -
EPS 1.26
Shares 31.00M
Beta 0.79
Inst. own 94%
Feb 9, 2015
Q4 2014 Cambrex Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 11, 2014
Cambrex Corp at Oppenheimer Healthcare Conference - Webcast
Oct 30, 2014
Q3 2014 Cambrex Corp Earnings Release
Oct 30, 2014
Q3 2014 Cambrex Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 10.92% 9.52%
Operating margin 14.79% 15.60%
EBITD margin - 21.19%
Return on average assets 7.74% 7.18%
Return on average equity 15.23% 16.21%
Employees 936 -
CDP Score - -

Address

One Meadowlands Plaza
E RUTHERFORD, NJ 07073
United States - Map
+1-201-8043000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cambrex Corporation (Cambrex) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics. The Company�s business is consisted of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Its products include active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company supplies its products and services globally to generic pharmaceutical companies. The Company�s owns 51% stake in Zenara Pharma (Zenara), which focuses on the formulation of final dosage form products. The Company�s products are sold through a combination of direct sales and independent agents.

Officers and directors

Steven M. Klosk President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gregory P. Sargen Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paolo Russolo President of Cambrex Profarmaco Milano
Age: 68
Bio & Compensation  - Reuters
Shawn P. Cavanagh Chief Operating Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
William M. Haskel Chief Compliance Officer, Senior Vice President, General Counsel, Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
James G. Farrell Vice President, Corporate Controller
Age: 47
Bio & Compensation  - Reuters
Aldo Magnini Managing Director of Cambrex Profarmaco Milano
Age: 61
Bio & Compensation  - Reuters
Shlomo Yanai Non-Executive Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
James Francis Winschel Jr. Director
Age: 65
Bio & Compensation  - Reuters
Rosina B. Dixon M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters